Acro Biomedical Co., Ltd. (ACBM)

AI-Powered SEC Filing Analysis

Annual Report Filed: 2026-02-11

Key Insights

  • The company has reported no revenue and no profits for the past 3 years, indicating a lack of commercial success for its products.
  • The company's lease agreements in Hong Kong suggest it may be focused on international expansion, but this strategy has not yet translated to financial results.
  • The CEO and minority shareholders have maintained control of the company, with little evidence of outside investment or change in ownership structure.
Filing tone (AI): Negative
View Original Filing →
Current Report Filed: 2026-01-08

Key Insights

  • Acro Biomedical dismissed its previous auditor KCCW Accountancy Corp. and appointed Weinberg & Company as its new independent registered accounting firm.
  • There were no disagreements between the company and the previous auditor KCCW on any accounting, financial reporting, or audit-related matters.
  • The previous auditor's report contained an explanatory paragraph regarding uncertainty about the company's ability to continue as a going concern.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Acro Biomedical Co., Ltd. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.